Observador | Pro Bono | Obesity medication: what if the State paid?
Whether or not to reimburse obesity medication “is a structural and important decision for the future of these patients, as well as for the healthcare system from a sustainability perspective,” says Ricardo Rocha.
In the latest episode of “Pro Bono”, an initiative by Rádio Observador and Abreu Advogados, the specialist in regulatory and market access matters in the Healthcare, Life Sciences & Pharmaceuticals sector explains what is at stake with the reimbursement of these medicines by the Portuguese State.
Every Wednesday at 3:15 pm, on the “Pro Bono” programme, Abreu Advogados and Rádio Observador help companies make decisions, understand the more complex aspects of the law, and clarify some of the main current affairs topics.
Watch the new episode here (available only in Portugese).
